Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-03-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology (Group) Co., Ltd. regarding the company's application to banks for a comprehensive credit line. It discusses the company's need for increased working capital due to business expansion and authorizes the chairman to sign related documents. The document is short (658 characters) and focuses on financing activities, specifically credit facilities. It does not contain financial statements or detailed financial data, nor is it a report or presentation. Therefore, it fits the category of Capital/Financing Update (CAP).
2019-03-28 Chinese
关于监事辞职及补选第六届监事会非职工代表监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a supervisory board member and the nomination of a replacement for the supervisory board of Anhui Anke Biotechnology (Group) Co., Ltd. It includes details about the resignation, the nomination process, and the resume of the nominated candidate. There are no financial statements, earnings data, or detailed management discussion. The document is a formal announcement about changes in the supervisory board, which falls under Board/Management Information (MANG). The document length is short and focused solely on board changes, not a full report or financial disclosure.
2019-03-28 Chinese
2019年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a 2019 first quarter earnings forecast (业绩预告) from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It provides estimated net profit figures for the quarter ending March 31, 2019, compared to the same period last year. It explicitly states that the forecast is unaudited and that detailed actual results will be disclosed in the official first quarter report later. The document is short (946 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results or key highlights. It is not a full Interim/Quarterly Report (IR) because it lacks actual financial statements or substantive financial data, only forecasts. Therefore, the correct classification is ER with high confidence. Q1 2019
2019-03-28 Chinese
2018年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2018年度内部控制自我评价报告' which translates to '2018 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control evaluation for the fiscal year ending December 31, 2018. The content includes detailed descriptions of internal control systems, governance, risk assessment, and control activities, as well as conclusions on the effectiveness of internal controls. It references regulatory frameworks and standards related to internal control but does not present full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). The document is a standalone report focused on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR). The length (5718 characters) and detailed content confirm it is the report itself, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-03-28 Chinese
关于获批建设肿瘤精准治疗技术及产品国家地方联合工程研究中心的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval to establish a national and local joint engineering research center focused on tumor precision treatment technology and products. It includes details about the center's name, main responsible unit, construction content, and the impact on the company. There are no financial statements, quarterly or annual results, nor is it a report or presentation. It is a formal announcement about a significant company development related to research and innovation infrastructure. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a company project approval, which fits best under Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2019-03-27 Chinese
非公开发行股票上市保荐书
Capital/Financing Update Classification · 100% confidence The document is titled as a "非公开发行股票上市保荐书" which translates to "Non-public Offering Stock Listing Sponsorship Letter." It is issued by a sponsoring institution (underwriter) and addresses the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC). The document details the non-public issuance of new shares, including the number of shares, pricing, total funds raised, and the allocation of shares to specific investors. It also includes financial data for the issuer over several years, descriptions of the issuance process, and the sponsor's commitments and ongoing supervision arrangements. This document is a formal sponsorship and recommendation letter for the listing of newly issued shares on the stock exchange, which is a capital market financing activity. It is not an annual report, earnings release, or other financial report but rather a capital/financing update related to a specific stock issuance and listing approval process. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7856 characters) and content confirm it is a full sponsorship letter, not a brief announcement or certification, so it is not RPA or RNS.
2019-03-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.